Companies Embark On Partnership For Neurodegenerative Disease Research
CLINICAL LAB PRODUCTS
Quanterix Corp, Lexington, Mass, will join forces with UmanDiagnostics AB, Umeå, Sweden, to provide commercial access to an ultrasensitive single molecule array (Simoa) assay for the detection of neurofilament light in blood specimens.
Neurodegenerative diseases such as Alzheimer’s disease and Parkinson’s disease are debilitating conditions that are currently incurable. Such diseases typically result in progressive neurodegeneration that may start 20 to 30 years before any clinical symptoms are noticed.
Read the rest of the article at clpmag.com
Share this page